title: Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry.
abstract: OBJECTIVE
  We sought to determine whether an obesity paradox exists in the contemporary era of percutaneous coronary intervention (PCI) and to explore potential clinical factors that might contribute.
  
  
  BACKGROUND
  Previous studies have suggested that overweight and obese patients might have better outcomes after PCI than patients with a normal or low body mass index (BMI); however this "obesity paradox" remains poorly understood.
  
  
  METHODS
  We evaluated 4,762 patients undergoing PCI between April 1, 2004 and September 30, 2007, enrolled in the MIG (Melbourne Intervention Group) registry. Patients were classified as underweight, normal, overweight, class I obese, and class II to III obese, BMI <20, 20 to 25, 25.1 to 30, 30.1 to 35, and >35 kg/m(2), respectively. We compared in-hospital, 30-day, and 12-month outcomes.
  
  
  RESULTS
  As BMI increased from <20 to >35 kg/m(2), there was a statistically significant, linear reduction in 12-month major adverse cardiac events (MACE) (21.4% to 11.9%, p = 0.008) and mortality (7.6% to 2.0%, p < 0.001). Obesity was, with multivariate analysis, an independent predictor of reduced 12-month MACE and showed a trend for reduced 12-month mortality. At 12 months, obese patients had higher use of aspirin, clopidogrel, beta-blockers, renin-angiotensin system blockers and statins.
  
  
  CONCLUSIONS
  Compared with normal-weight individuals, overweight and obese patients had lower in-hospital and 12-month MACE and mortality rates after PCI. Moreover, obese patients had a higher rate of guideline-based medication use at 12 months, which might in part explain the obesity paradox seen after PCI.
authors.affiliation: Department of Cardiology, Austin Health, Melbourne, Australia.
authors.forename: Terase
authors.initials: T
authors.lastname: Lancefield
authors.forename: David J
authors.initials: DJ
authors.lastname: Clark
authors.forename: Nick
authors.initials: N
authors.lastname: Andrianopoulos
authors.forename: Angela L
authors.initials: AL
authors.lastname: Brennan
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Reid
authors.forename: Jennifer
authors.initials: J
authors.lastname: Johns
authors.forename: Melanie
authors.initials: M
authors.lastname: Freeman
authors.forename: Kerrie
authors.initials: K
authors.lastname: Charter
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Duffy
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Ajani
authors.forename: Joseph
authors.initials: J
authors.lastname: Proietto
authors.forename: Omar
authors.initials: O
authors.lastname: Farouque
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000401:mortality; D015992:Body Mass Index; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000150:complications / Q000401:mortality / Q000628:therapy*; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000401:mortality; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014739:Victoria
chemical_list: D002317:Cardiovascular Agents